StockNews.AISignal intelligence

Public signal · 1-minute delayed

Signal brief

Source-backed market context you can read and share without an account.

Browse signals
OGNBullishM&Anews
High materiality10/10

Sun Pharma to acquire Organon in $11.75 billion cash deal

Apr 26, 2026, 7:53 PM EDT5 sourcesAI-analyzed
Why it may matterVerify against the original reporting

The acquisition at $14 per share signifies a premium to current trading prices, likely driving investor optimism. Historically, similar transactions have resulted in positive price momentum for acquired stocks.

AI summary

What happened, with direct paths to the underlying reporting

Sun Pharmaceutical Industries has announced its plan to acquire Organon for $14 per share, valuing the company at $11.75 billion. This transaction aims to leverage complementary portfolios and enhance long-term value, pending regulatory and stockholder approvals.

  • Sun Pharma will acquire Organon for $14 per share in cash.
  • The deal values Organon at an enterprise value of $11.75 billion.
  • Transaction aims to create significant long-term value through combined resources.
  • Acquisition approved by both companies' boards, pending regulatory approvals.
  • Organon reported $6.2 billion in revenue for FY2025.

How to read this signal

Transparent limits for an AI-generated research aid

StockNews.AI groups source reporting, classifies the event, and measures subsequent price movement. This is informational research, not investment advice. Prices may be delayed or unavailable.

Related signals

More source-backed signals connected by company or event